Rheumatoid arthritis patients who fail on a first-time trial of tumor necrosis factor inhibitor therapy should change to a biologic with a different mechanism of action, according to Dr. Daniel E. Furst, who is a professor of rheumatology at the University of California, Los Angeles.
If by 12 weeks, you have no response at all, then it’s time to change. If, on the other hand, by 12 weeks you have a little response — just the begining of a change in the DAS [disease activity score], etc. — then it really makes sense to wait another 8-12 weeks before deciding to go to a different mechanism of action.
Read the latest news about rheumatoid arthitis and all things internal medicine at Internal Medicine News.